Cytokinetics (CYTK) Stock Forecast & Price Target

$49.86 -1.23 (-2.41%)

(As of 11/20/2024 ET)

Cytokinetics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
4

Buy
12

Based on 16 Wall Street analysts who have issued ratings for Cytokinetics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, and 12 have given a buy rating for CYTK.

Consensus Price Target

$83.67
67.80% Upside

According to the 16 analysts' twelve-month price targets for Cytokinetics, the average price target is $83.67. The highest price target for CYTK is $120.00, while the lowest price target for CYTK is $60.00. The average price target represents a forecasted upside of 67.80% from the current price of $49.86.

Get the Latest News and Ratings for CYTK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cytokinetics and its competitors.

CYTK Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	14 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$83.67	$83.93	$80.27	$59.87
Forecasted Upside	67.80% Upside	52.76% Upside	40.03% Upside	87.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

CYTK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CYTK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cytokinetics Stock vs. The Competition

Type	Cytokinetics	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	67.80% Upside	26,904.61% Upside	9.81% Upside
News Sentiment Rating	Neutral News See Recent CYTK News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00	+40.93%
11/18/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00	+138.95%
11/8/2024	Royal Bank of Canada 4 of 5 stars	L. Timashev Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$80.00	+43.27%
10/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
9/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$65.00 ➝ $71.00	+27.26%
9/4/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$78.00 ➝ $78.00	+44.10%
Get the Latest News and Ratings for CYTK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.
8/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Choi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$85.00 ➝ $60.00	+6.80%
6/4/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$122.00 ➝ $92.00	+89.81%
5/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$86.00 ➝ $70.00	+45.20%
5/23/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$70.00 ➝ $60.00	+20.53%
5/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$100.00 ➝ $95.00	+92.19%
5/23/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $70.00	+42.80%
5/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$107.00 ➝ $106.00	+65.08%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $99.00	+49.03%
1/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$61.00 ➝ $92.00	+8.49%
1/5/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Equal Weight	$60.00 ➝ $90.00	+1.99%
8/15/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/15/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%
8/15/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:53 AM ET.

CYTK Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Cytokinetics is $83.67, with a high forecast of $120.00 and a low forecast of $60.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
: According to analysts, Cytokinetics's stock has a predicted upside of 67.80% based on their 12-month stock forecasts.
: Cytokinetics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, and Royal Bank of Canada in the past 90 days.
: Analysts like Cytokinetics less than other "medical" companies. The consensus rating score for Cytokinetics is 2.75 while the average consensus rating score for "medical" companies is 2.80. Learn more on how CYTK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

This page (NASDAQ:CYTK) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Stock Forecast & Price Target